Experimental cell therapy targets scar tissue in failing hearts
NCT ID NCT06902896
First seen Feb 20, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This early-phase study tested a new treatment called CAR-DC in 8 adults with end-stage dilated cardiomyopathy, a condition where the heart becomes enlarged and weak. The therapy uses specially engineered immune cells to target a protein (FAP) linked to scar tissue in the heart. The main goals were to check safety and side effects, while also measuring any changes in heart function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310009, China
Conditions
Explore the condition pages connected to this study.